Vallaurix

Vallaurix is a Singapore-based biotechnology company and a subsidiary of iX Biopharma, specializing in the development of novel therapies using its proprietary WaferiX sublingual drug delivery platform. The WaferiX technology allows for the rapid absorption of active compounds through the sublingual mucosa, bypassing first-pass metabolism and offering potentially faster onset of action and improved bioavailability. The company's pipeline focuses on pain management, medicinal cannabis, and male health, with lead programs including Wafermine for acute pain and various ketamine-based formulations. Vallaurix manages the research, development, and clinical trial activities for the iX Biopharma group, aiming to repurpose established drugs for better patient outcomes.